Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Periodic adalimumab versus standard step-care as initial treatment for Crohn's disease
NL-OMON52419Phase 4Recruiting
- Sponsor
- Maastricht University
- Start
- Dec 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of adalimumab, prednisone and budesonide in Crohn's disease and inflammatory bowel disease (IBD) (2 arms), sponsored by Maastricht University. Primary endpoints: Yearly quarters of corticosteroid-free clinical and biochemical remission, Disease progression and 2 more. Started Dec 2019; status: recruiting.
02
Drugs
03
Conditions
Crohn's diseaseinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NL-OMON52419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52419.